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ABSTRACT	 	
The present work is aim to Develop UV spectrophotometry method for the estimation of Apixaban in its 
dosage forms. Analysed the marketed formulations for their reliability and accuracy and performed the 
recovery studies for the developed UV spectrophotometric method. The developed method was validate 
for its accuracy precision reproducibility. On the basis of results the UV spectrophotometric method 
developed for the determination of Apixaban is found to be precise, accurate and cost effective. Hence 
this method can be used for routine analysis of Apixaban in bulk and pharmaceutical dosage forms.	
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INTRODUCTION	Development	 of	 a	 simple,	 reliable	 and	 accurate	method	for	the	assay	of	apixaban tablet	dosage	form	by	UV	and	validate	 the	method	 for	 its	 repeatability	and	 reproducibility.	Apixaban,	 sold	under	 the	 trade	name	Eliquis	among	others,	is	an	anticoagulant	used	to	treat	and	prevent	blood	clots	and	to	prevent	stroke	in	people	with	atrial	 fibrillation.[1,	2]	Specifically	 it	 is	used	 to	 prevent	 blood	 clots	 following	 hip	 or	 knee	replacement	and	in	those	with	a	history	of	prior	clots.	It	is	used	as	an	alternative	to	warfarin	and	does	not	require	monitoring	by	blood	tests.	Apixaban	was	approved	for	medical	use	in	the	United	States	 in	 2012.	 A	 month	 supply	 in	 the	 United	Kingdom	costs	the	NHS	about	£57	as	of	2019.[2]	In	the	United	 States	 the	 wholesale	 cost	 of	 this	 amount	 is	about	 $427.[4]	 In	 2016	 it	 was	 the	 123rd	 most	
prescribed	medication	in	the	United	States	with	more	than	5	million	prescriptions.[5]	
 
Figure 1: Chemical Structure of Apixaban Apixaban	is	a	highly	selective,	orally	bioavailable,	and	reversible	 direct	 inhibitor	 of	 free	 and	 clot-bound	factor	 Xa.	 Factor	 Xa	 catalyzes	 the	 conversion	 of	prothrombin	 to	 thrombin,	 the	 final	 enzyme	 in	 the	coagulation	cascade	that	is	responsible	for	fibrin	clot	formation.[10]	 Apixaban	 has	 no	 direct	 effect	 on	platelet	 aggregation,	 but	 by	 inhibiting	 factor	 Xa,	 it	indirectly	 decreases	 clot	 formation	 induced	 by	thrombin.[6]	
MATERIALS	AND	METHODS	
Materials:	Apixaban	received	as	a	gift	sample	 from	Sun	Pharmaceuticals	pvt.	Ltd.	and	the	authenticity	of	purity	of	the	sample	was	certified	by	same.	ELIQUIS-2.5mg,	ELIQUIS-5mg	marketed	samples	are	obtained	from	the	nearby	stores.	
Instrument:	 In	developing	quantitative	method	 for	determining	 unknown	 concentration	 of	 	 analyte	 by	absorption	 spectrophotometry,	 UV	 visible	 double	beam	 spectrophotometer,	 Systronics-2203(smart),	Matched	quartz	cells	1	cm	path	length.		
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Solvent	 Selection:	 Solvent	 selection	 was	 made	 on	the	basis	of	solubility	studies	with	pure	drug	several	solvents	were	proposed	for	solubility	they	are	Water,	Sodium	Hydroxide,	Methanol,	Ethanol.	From	solvents	studies	 it	was	 found	 that	 the	 pure	 drug	was	 freely	soluble	in	Water,	Methanol,	Ethanol.	
Wave	Length	selection:	Standard	stock	solution	of	Apixaban	was	prepared	by	dissolving	50	mg	of	drug	in	50ml	of	water	and	diluted	to	required	volume	with	same			solvent.	Then	the	solution			was	further	diluted	to	 get	 concentration	of	 10µg/ml.	 	 The	 solution	was	scanned	inn	U.V.	region	from	200-400nm.The	λ	max	of	drug	was	found	to			be	at	278nm	for	Apixaban.	
Table 1: Wave length selection 
S.no.	 Wave length	 Absorbance	
1	 272	 0.361	
2	 273	 0.378	
3	 274	 0.384	
4	 275	 0.392	
5	 276	 0.398	
6	 277	 0.410	
7	 278	 0.445	
8 279 0.424 
9 280 0.397 
10 281 0.375 
 
Figure 2: Spectra of Apixaban	
Methods:	
Preparation	 of	 stock	 solution:	 Standard	 stock	solution	of	Apixaban	was	prepared	by	dissolving	50	mg	of	drug	in	50ml	of	water	and	diluted	to	required	volume	with	same			solvent.	Then	the	solution			was	further	diluted	to	get	concentration	of	10µg/ml.		The	solution	 was	 scanned	 inn	 UV	 region	 from	 200-400nm.The	λ	max	of	drug	was	found	to			be	at	278nm	for	Apixaban.	
Beers	law	concentration	range:	The	stock	solution	was	suitably	diluted	with	water	to	get	a	concentration	range	 from	 10-80µg/ml	 and	 their	 absorbance	 was	measured	 at	 278nm.	 Using	 the	 absorbance	 values	against	concentration	calibration	curve	was	plotted.		From	 the	 graph	 it	 was	 found	 that	 Apixaban	 obeys	beers	law	between	10-70	µg/ml.	
Analysis	 of	 formulation:	 10	 Tablets	 were	 finely	powdered.	An	accurately	weighed	quantity	of	tablet	powder	equivalent	 to	 about	50mg	of	Apixaban	was	transferred	 to	50	ml	 standard	 flask.	 The	 content	 of	flask	was	mixed	with	 	 30	ml	water	 and	 shaken	 	 to	dissolve	the	active	ingredients	and	then	make	up	to	the	volume	with	water	.The	solution	was	filtered	and	then	 filtrate	 diluted	 with	 water	 to	 give	 the	concentration	range	50	µg/ml.	Absorbance	values	of	samples	solution	was	recorded	at	278nm.	Sample	absstandard	abs × 50wt	of	sample × 501 × wt	of	std	taken50 × 150 × average	weight	
Table 2: calibration curve of Apixaban 
S.no.	 Concentration	 Absorbance	
1.	 10	 0.103	
2.	 20	 0.164	
3.	 30	 0.265	
4.	 40	 0.316	
5.	 50	 0.425	
6.	 60	 0.500	
7.	 70	 0.573	
Slope	 = 0.008131 
Correlation coefficient	 = 0.9957 
 
Figure 3: Calibration curve of Apixaban	
Precision	The	 closeness	 of	 agreement	 	 between	 a	 series	 of	measurements.	 Multiple	 sampling	 of	 homogeneous	samples	under	prescribed	condition,	precision	is	two	types	Repeatability	and	Reproducibility.	
Repeatability	 (system	 precision):	 50µg/ml	concentration	 solution	 of	 Apixaban	 was	 prepared	whose	absorbance	of	measured	six	times			for	which	relative	standard	deviation	is	calculated.		
Acceptance	criteria:	The	relative	standard	deviation	for	preparation		should	not	be	more	than	2%.	
Reproducibility(method	precision):	six	individual	preparations	 of	 Apixaban	 was	 prepared	 with	 a	concentration	 of	 50µg/ml.	 Whose	 absorbance	measured	at	278nm.	
Acceptance	criteria:	The	relative	standard	deviation	for	preparation		should	not	be	more	than	2%.	
Solution	 stability:	 50µg/ml	 concentration	 solution	of	 Apixaban	 was	 prepared	 and	 the	 solution	 whose	absorbance	is	measured		for	every	half	an	hour	for	90	
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minutes	and	the	solution	was	found	to	be	stable	up	to	90	minutes.	
Table 5: Solution stability of apixaban 
S.no	 Time	 Absorbance	
1.	 1 min	 0.524	
2.	 60 min	 0.520	
3.	 90 min	 0.480	
Table 6: System precision of apixaban 
Sl.no	 Repeatability (conc) µg/ml	 Absorbance	
1	 50	 0.429	
2	 50	 0.437	
3	 50	 0.441	
4	 50	 0.468	
5	 50	 0.451	
6	 50	 0.499	
	 Average	 0.445833	
	 Standard deviation	 0.013512	
	 %RSD 0.030307 
Table 7: Method precision of apixaban 
S.no. Concentration (µg/ml) Absorbance Average 
1 
50 
0.441 0.4325 0.424 
2 0.434 0.4345 0.435 
3 0.44 0.44 0.44 
4 0.46 0.462 0.464 
5 0.445 0.4555 0.466 
6 0.45 0.4505 0.451 
Average 0.4455 
Standard deviation 0.012062 
%RSD 0.027076 
Limit	 of	 detection:	 The	 detection	 limit	 of	 an	individual	analytical	procedure	is	the	lowest	amount	of	analyte	in	a	sample	which	can	be	detected	but	not	necessarily	quantitated	as	an	exact	value.	
Table 8: LOD of Apixaban 
        Sl.no.	       Parameter	 Apixaban	
             1	 Slope	 0.008131	
             2	        Standard deviation	 0.013512	
             3	              LOD	 4.895579	
Limit	of	quantitation:	The	 limit	of	quotation	of	an	individual	analytical	procedure	is	the	lowest	amount	of	 analyte	 in	 a	 sample	which	 can	 be	 quantitatively	determined	 with	 precision	 and	 accuracy	 .the	quantitation	 limit	 is	 a	 parameter	 of	 quantitative	assays	for	low	levels	of	compounds	in	sample	matrix	and	 is	 used	 particularly	 for	 the	 determination	 of	impurities	and	degradation	product.	
Table 9: LOQ of Apixaban 
        Sl.no.	       Parameter	 Apixaban	
             1	 Slope	 0.008131	
             2	        Standard deviation	 0.013512	
             3	              LOQ	 14.83509	
Accuracy		Accuracy	of	method	is	the	closeness	of	the	measured	value	 to	 the	 true	 value	 for	 the	 sample.	 Accuracy	 is	usually	 determined	 by	 recovery	 studies.	 Recovery	studies	are	performed	by	spiking	pure	powdered	into	the	sample	solution.	The	spiked	samples	prepared	at	a	concentration	range	of	80%,	100%,	120%.	
Table 10: Accuracy of Apixaban 
S.no	 Conn	 Mg found	 Mg added	 % Recovery	
1	 80	 0.005016	 0.005	 100.316	
2	 100	 0.004976	 0.005	 99.5294	
3	 120	 0.00497	 0.005	 99.41	The	 sample	 solution	 was	 prepared	 to	 get	 a	concentrate	 range	 of	 40µg/ml,	 50µg/ml,	 60µg/ml,	into	which	5mg	of	pure	powdered	 is	been	added	to	get	 80%,	 100%,	 120%	 concentration	 range.	 The	percentage	 recovery	 is	 calculated	 for	 these	concentrations	from	absorbance	obtained.		The	percentage	recovery	was	calculated	by	using	the	following	formula;											Percentage	recovery	=	:;<=>?	<@?:A>BC:;<=>?	:CCBC 				×100	
Table 3: Quantitative estimation of apixaban (Eliquis-2.5mg) 
S.no.	 Concentration (µg/ml) Label 
Claim	 Amount Present	 % of label      claim	 %deviation	
1	 30	 2.5	 0.002453	 98.11321	 0.0189	
2	 40	 2.5	 0.002524	 100.9494	 -0.0094	
3	 50	 2.5	 0.002512	 100.4706	 -0.0047	
4	 60	 2.5	 0.002545	 101.8	 -0.018	
5	 70	 2.5	 0.002641	 98.4293	 0.0158	
Table 4: Quantitative estimation of apixaban (Eliquis-5mg) 
S.no.	 Concentration (µg/ml) Label 
Claim	 Amount Present	 % of label      claim	 %deviation	
1	 30	 5	 0.005075	 101.5094	 -0.015	
2	 40	 5	 0.004921	 98.41772	 0.0159	
3	 50	 5	 0.004976	 99.52941	 0.0048	
4	 60	 5	 0.00491	 98.2	 0.018	
5	 70	 5	 0.004956	 99.1274	 0.0088	
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Acceptance	 criteria:	The	 percentage	 recovery	 	 for	the	spiked	preparation	should	be	within	98-102	%.	
Ruggedness:	The	extent	to	which	is	turned	precision	should	 be	 established	 depends	 on	 circumstances	which	 the	 procedure	 is	 intended	 to	 be	 used.	Intermediate	precision	expresses	with	in	laboratory	variation	 ie.,	 different	 days,	 different	 analysts,	different	 equipment’s.	 The	 procedure	 followed	 for	this	is	the	same	followed	in	the	method	precision	was	repeated	 on	 two	 different	 days	 by	 two	 different	analyst	 the	 result	 for	 the	 intermediate	 precision	recorded	in	the	table.		
Table 11:  Ruggedness of Apixaban 
Analyte	 Concentration 
(µg/ml)	 Absorbance	 % RSD	
Analyte-1	 50 	 0.445	 0.27	
Analyte-2	 50	 0.515	 1.54	
Acceptance	criteria:	The	relative	standard	deviation	for	the	preparation	should	not	be	more	than	2%	
Robustness:	Robustness	of	the	method	is	its	ability	to	 remain	 unaffected	 by	 small	 ranges	 in	 parameter	such	 as	 changes	 in	 wavelength,	 changes	 in	 pH,	changes	in	temperature	etc.	Robustness	examines	the	effect	 of	 operational	 parameters	 on	 the	 analytical	method.	 50µg/ml	 concentration	 of	 Apixaban	 was	prepared.	 whose	 absorbance	 measured	 in	 two	different	wavelength	closer	to	the	λmax.	of		the	drug.	
Table 12: Robustness of Apixaban 
Sl.No	 Concentration 
(µg/ml)	 Wave length	 Absorbance	
1	 50	 276	 0.451	
2	 50	 278	 0.453	
3 50 280 0.450 
Table 13: System suitability parameter of apixaban 
S.n
o. Parameter 
Requirem
ent 
Result
s 
Accepta
nce 
criteria 
1 Linearity 
Corr. 
Coefficie
nt 
0.998 < 1% 
2 Repeatability % RSD 
0.0303
07 < 2% 
3 Reproducibility % RSD 0.0270 < 2% 
4 LOD  4.895579 < 3% 
5 LOQ  14.83507 <10% 
6 Accuracy % Recovery 
99.4-
100.3 
98-
102% 
7 Ruggedness % RSD analyst-1 0.278 < 2% 
  % RSD analyst-2 1.540 < 2% 
8 Robustness No limits ----- 
No 
change 
in 
absorban
ce 
Formulation1 98.11-101.8 
Formulation2 98.2-101.5 
RESULTS	AND	DISCUSSIONS		Under	UV	spectral	analysis	 ,	the	absorption	maxima	(λmax)	 of	 Apixaban	 was	 observed	 as	 278	 nm	 and	tabulated	 in	 Table	 1.	 Obeyance	 to	 Beer’s	 law	 was	confirmed	by	the	linearity	of	the	calibration	curve	of	Apixaban,	 which	 is	 represented	 in	 and	 Figure	 2.	Apixaban	showed	 the	 linearity	 in	 the	 concentration	range	 of	 	 10-70µg/ml.	 The	 data	 regarding	 the	calibration	 curves	 are	 given	 in	 Table	 2.	 The	quantitative	 estimation	 was	 carried	 out	 in	 tablet	formulations	 by	 taking	 concentrations	 of	 10-70	µg/ml.	The	 regarding	 the	quantitative	estimation	 is	given	in		Table	3,4.	The	brands	of	formulations	shows	the	 percentage	 purity	 values	 range	 from	 	 98.11-101.8%.	The	percentage	deviation	values	were	found	to	 be	 between	 	 -0.004	 to	 0.0189.	 The	 quantitative	results	obtained	were	subjected	to	statistical	analysis	to	 find	 out	 standard	 deviation	 values.	 The	 relative	standard	 deviation	 values	 are	 <2%,	 indicating	 the	precision	 of	 the	 methodology	 3.	 The	 repeatability,	reproducibility,	 ruggedness	 of	 the	 method	 was	conformed	as	per	ICH	guidelines.	The	data	is	given	in	Tables	 6,	 7.	 The	 results	 obtained	 expresses	 the	precision	of	the	given	method.	The	validation	of	the	proposed	method	was	further	confirmed	by	recovery	studies.	The	recovery	data	is	given	in	Table	10.	The	recovery	 values	 vary	 from	 	 99.4-100.31%	 	 	 	 this	serves	as	a	good	index	of	accuracy	of	the	method.	
CONCLUSION	Method	developed	for	the	determination	of	Apixaban	by	using	U.V.	spectrophotometric,	On	the	basis	of	our	experimental	 results	 we	 conclude	 that	 the	 U.V.	spectrophotometric	 method	 developed	 for	 the	determination	 of	 Apixaban	 is	 found	 to	 be	 precise,	accurate	and	cost	effective.	Hence	this	method	can	be	used	 for	 routine	 analysis	 of	 Apixaban	 in	 bulk	 and	pharmaceutical	dosage	forms.	
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